|
|
Victoria |
|
Steadman |
|
Vice President of Business Development and Integrated Partnerships |
Sai Life Sciences Ltd |
https://proventainternational.com/wp-content/uploads/2022/03/Victoria-Steadman.jpg |
Vicky Steadman, PhD is Vice President, Business Development and Integrated Partnerships at Sai Life Sciences. A medicinal chemist by background, Vicky has nearly 20 years industry experience in Big Pharma and within CROs. She is named on over 25 peer reviewed publications and patents including a Nature paper and has worked in the therapeutic areas of anti-virals, antibiotics and neuroscience. Vicky has a BSc in chemistry from Imperial College and a PhD in organic chemistry from the University of Cambridge. She is a fellow of the Royal Society of Chemistry. |
|
|
Maneesh |
|
Pingle |
|
EVP & Head of Discovery Services |
Sai Life Sciences |
https://proventainternational.com/wp-content/uploads/2022/03/Maneesh.jpg |
Maneesh Pingle PhD is Head of Discovery Business Development at Sai Life Sciences. A Pharmacist and Medicinal Chemist by training, he has served on the faculty of Weill Cornell Medicine, co-founded two startups focused on drug discovery platforms and now leads the Business development team at Sai to support innovator companies advance their drug discovery programs. Maneesh received his PhD from Purdue University. |
|
|
Tim |
|
Hohm |
|
Director of Commercial Strategy and Business Development |
Optibrium |
https://proventainternational.com/wp-content/uploads/2022/03/Tim-Hohm.jpg |
Tim has a PhD in Computational Biology from ETH Zurich and research experience with optimisation heuristics and quantitative modelling of gene regulatory networks. Tim’s natural sciences background is complemented with an MBA from the internationally recognised Copenhagen Business School. He is responsible for leading Optibrium’s commercial strategy and sales processes,
with a focus on further expanding the company’s global customer base.
Tim previously worked at Novo Nordisk as Senior Competitive Intelligence Manager where his role covered digital health and delivery technology with responsibilities including strategy development, defining target product profiles. |
|
|
Scott |
|
Lyon PhD |
|
Director of Business Development |
Optibrium |
https://proventainternational.com/wp-content/uploads/2022/03/Scott-Lyon-PhD.jpg |
Scott is Director of Business Development at Optibrium Limited, and based in California. He holds a BS in Chemistry from Carnegie Mellon University and a PhD in Chemistry from University of Arizona.
5 years ago, Scott joined Optibrium and returned to his roots, working with medicinal chemists, computational chemists and ADME scientists to enable them to solve complex drug design challenges. A 25 year veteran in the drug discovery software space, Scott is fueled by the promise of chemists leveraging their expert knowledge with AI and Machine Learning to advance drug discovery in the future. |
|
|
Barry |
|
A. Bunin |
|
Collaborative Drug Discovery |
CEO |
https://proventainternational.com/wp-content/uploads/2022/04/Barry-Bunin.jpg |
|
|
|
Steve |
|
McCloskey |
|
CEO and Co-Founder |
Nanome |
https://proventainternational.com/wp-content/uploads/2021/09/IMG_3943-scaled-e1631894869888.jpg |
Steve is the Founder and CEO at Nanome, Inc and is an alumnus from the first class of Nanoengineering at the University of California, San Diego. He has been directing the development of a Virtual Reality based application for molecular design which helps scientists around the world develop better medicines. Steve leads a growing team based in San Diego comprised of technical developers as well as the business development team and has been instrumental in securing millions of dollars in funding for Nanome. |
|
|
Abdulkader |
|
Rahmo |
|
President & Chief Scientific Officer |
SMSbiotech |
https://proventainternational.com/wp-content/uploads/2021/08/Abdulkader-Rahmo.jpg |
Abdulkader Rahmo, PhD, co-founder, President and Chief Scientific Officer of SMSbiotech, holds a bachelor’s degree in biochemistry from the Swiss Federal Institute of Technology (ETH) and a PhD from the University of Southern California (USC), in the field of Biochemistry. In 2015 he co founded SMSbiotech Inc. based on his research in stem cell biology, He has over 30 years’ experience in research and applications; he has dedicated the past eleven years to SMS cell discovery and development. Working with one of the world’s leading patent firms, he holds 3 patents and has filed 10 patents related to Small Mobile Stem cell technology. His main scientific interest is in the field of regenerative medicine and age-related diseases with emphasis on lung degenerative diseases. |
|
|
Yuhua |
|
Ji |
|
Vice President, Drug Discovery |
Grace Science, LLC |
https://proventainternational.com/wp-content/uploads/2021/02/Yuhua-Ji-1.jpg |
Yuhua Ji, Ph.D, has broad experiences in drug discovery and development. She has a proven track record of building team from the ground up. She led and contributed to over ten development candidates and IND-filings. Dr. Ji has extensive expertise in medicinal chemistry, CMC and preclinical development of small molecules. She is the principal inventor of revefenacin and named as the inventor on over 100 patents and the author of over 20 publications. Currently, she is VP of drug discovery at Grace Science. Previously, Dr Ji was the head of Medicinal Chemistry at Zai Lab and IND director at Virogin Biotech. During her years at Path, She led discovery chemistry and CMC, and supported several clinical development programs. She led the discovery and early development of YUPELRITM at Theravance |
|
|
Prasun |
|
Mishra |
|
CEO, Founder / CEO, Founding President |
r, Agility Pharmaceuticals / American Association for Precision Medicine (AAPM) |
https://proventainternational.com/wp-content/uploads/2020/05/Prasun-Mishra-Pic-Prasun-Mishra-e1589209319911.jpeg |
Dr. Prasun Mishra is an investor, co-founder and board member of a few US based corporations. He leads the research efforts focused on preventing and curing COVID-19, cancer, and other chronic diseases. He has numerous publications, patents and several drugs in clinical trials to his credit. He is a recipient of over 40 prestigious awards and honors, including a recent recognition by Thrive Global and Authority Magazine as a ‘Social Impact Hero’. Due to his unique perspective and selfless service, he is a highly respected and sought-after mentor to many. |
|
|
Mike |
|
Petrassi |
|
Vice President, Discovery Chemistry |
Protego Biopharma |
https://proventainternational.com/wp-content/uploads/2021/02/Mike-Petassi.jpg |
H. Michael Petrassi serves as Head of Discovery Chemistry at Protego bringing over 20 years of medicinal chemistry and drug discovery experience. Michael was most recently San Diego Site Head and Vice President of Medicinal Chemistry at Treeline Biosciences. Prior to Treeline he was Vice President of Medicinal Chemistry at Calibr at Scripps Research. He led discovery research teams across multiple disease areas translating innovative Scripps Research discoveries into clinical stage compounds. Michael began his career in drug discovery at the Genomics Institute of the Novartis Research Foundation, where he led the medicinal chemistry efforts on several projects. Most notably in regenerative medicine that delivered clinical stage assets into the Novartis pipeline. Michael earned his Ph.D. in organic chemistry from the Scripps Research Institute, and a B.S.c in chemistry from the State University of New York at Fredonia. |
|
|
Valery |
|
Polyakov |
|
Director, Head of Computational Chemistry |
Sutro Biopharma |
https://proventainternational.com/wp-content/uploads/2020/01/Valery-Polyakov.jpg |
Valery Polyakov is a Director of Computational Chemistry at SUTRO Biopharma. He works in the field of AI and Machine Learning leveraging Big Data to facilitate drug discovery. He also oversees computational infrastructure development for the needs of Chemistry. Prior to that, he worked at Novartis, developing new drugs for treating cancer and infectious diseases. A compound that he co-invented is now in Phase II of clinical trials. Before that, he worked for Sanofi in molecular modeling and chemoinformatics groups. He holds a Ph.D. in Chemistry from Kiev Tshevchenko University (Ukraine) and prestigious awards including the Fulbright Scholarship. Valery authored more than 36 published papers and 22 issued patents or published patent applications. In his free time Valery plays underwater hockey and freedives. |
|
|
Bill |
|
Shirley |
|
Senior Director, Structural Chemistry |
Gilead Sciences |
https://proventainternational.com/wp-content/uploads/2021/02/Bill-Shirley.jpg |
Bill received his Ph.D. from Wesleyan University in Middletown, CT, for his work in ab initio method development. He subsequently worked with Roald Hoffmann at Cornell where he applied semi-empirical methods to the design of novel materials. He then joined Charles L. Brooks III at Scripps in San Diego to use molecular dynamics to understand the determinates of protein structure. Subsequently, he was employed at several San Diego & Bay Area biotechnology and small pharmaceutical companies (e.g. CombiChem, Neurocrine) as a computational chemist or as a cheminformatician.
After a few years of increasing his software knowledge (as a solution architect and product manager at Biovia), he returned to chemical informatics with a data science focus at Novartis in Emeryville. After the site’s transition away from therapeutic research for virology and bacteriology, he was asked to join Gilead. At Gilead, he leads the Research Informatics group and is responsible for data systems, research workflow systems and predictive chemical informatics. |
|
|
Devin |
|
Swanson |
|
Director, External Innovation |
Johnson & Johnson Innovative Medicines |
https://proventainternational.com/wp-content/uploads/2022/03/Devid-Swanson.jpg |
Devin is a Principal Scientist, External Innovation at Janssen Pharmaceutical companies of Johnson & Johnson based in San Diego, CA. With over twenty years of drug discovery experience, Devin has made substantial contributions to twelve projects across the neuroscience, pain, and immunology therapeutic areas. This work has led to six clinical candidates, 15 peer reviewed publications (5 first author), and 15 patent applications-issued patents. In his current role, Devin is looking to partner and license platforms and assets in the research and development, pharmaceutical space. Devin holds a BA from Boston University, an MS from UC San Diego, and an MBA from the University of Southern California. |
The Westin St. Francis San Francisco on Union Square
Payment Securely powered by stripe
